WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies, academic institutions, health plans, and patient advocacy groups. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations.
WIN will use the HTG EdgeSeq system and products for lung cancer research and clinical trial investigations aimed to develop gene expression molecular profiling in vitro diagnostic tests for multiple targeted therapies. HTG EdgeSeq technology will enable WIN members to measure quantitative expression of both message (mRNA) and microRNA (miRNA) from very small, challenging sample types such as formalin-fixed, paraffin-embedded (FFPE) tissues and plasma from blood. Automated on the HTG EdgeSeq system, HTG EdgeSeq technology couples HTG’s proprietary nuclease protection chemistry with Next-Generation Sequencing (NGS).
HTG expects its membership in WIN will provide important resources and information for selection of novel therapies for a series of lung cancer trials to better predict outcomes in lung cancer patients than currently accepted genomic analysis alone.
“We are thrilled to partner with WIN to investigate new assays to better diagnose and treat patients afflicted with lung cancer,” stated TJ Johnson, HTG Molecular Chief Executive Officer.
Headquartered in Tucson, Arizona, HTG Molecular Diagnostics’ mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing. Additional information is available atwww.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the use of our technology by Consortium members, expected benefits from our membership in the Consortium and the capabilities of our technology. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks inherent in molecular profiling research and development activities. These and other factors are described in greater detail in our quarterly report on Form 10-Q for the quarter ended March 31, 2015, filed with the Securities and Exchange Commission on June 8, 2015. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: email@example.com TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: firstname.lastname@example.org